Dec 9, 2024 12:01PM
Dec 9, 2024 12:00PM
Nov 14, 2024 09:00AM
Nov 7, 2024 04:05PM
Nov 5, 2024 04:13PM
Nov 5, 2024 04:05PM
Sep 27, 2024 04:31PM Poseida Therapeutics (PSTX) Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1
Sep 27, 2024 04:30PM
Sep 16, 2024 08:02AM
Sep 16, 2024 08:00AM
Aug 5, 2024 04:05PM
May 14, 2024 04:05PM
Apr 8, 2024 12:05PM
Apr 8, 2024 12:00PM Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Mar 13, 2024 04:05PM
Mar 13, 2024 04:05PM
Jan 4, 2024 08:05AM
Jan 4, 2024 08:00AM
Aug 7, 2023 09:08AM
Aug 7, 2023 09:01AM
Jul 5, 2023 08:02AM Poseida Therapeutics (PSTX) Announces FDA Clearance of Investigational NDA for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
Jul 5, 2023 08:00AM
Jan 31, 2023 04:07PM
Jan 31, 2023 04:05PM
Mar 10, 2022 04:05PM
Jan 10, 2022 08:04AM
Jan 10, 2022 08:00AM
Dec 20, 2021 08:04AM Poseida Therapeutics (PSTX) Announces FDA Clearance of IND Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors
Dec 20, 2021 08:00AM
Dec 13, 2021 08:00AM
Nov 9, 2021 04:05PM
Nov 9, 2021 08:05AM
Oct 1, 2021 08:05AM
Aug 30, 2021 08:00AM
Dec 5, 2020 01:45PM Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting
Nov 12, 2020 04:05PM
Nov 2, 2020 08:04AM
Nov 2, 2020 08:00AM
Sep 16, 2020 09:30AM
Sep 1, 2020 04:09PM
Aug 20, 2020 04:05PM
Aug 18, 2020 09:29AM Pre-Open Stock Movers 08/18: (SE) (RXT) (VNDA) Higher; (PSTX) (NBR) (KSS) Lower (more...)
Aug 17, 2020 06:06PM
Aug 17, 2020 04:24PM
Jan 8, 2018 06:32AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All